# The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)

> **NCT00640640** · NA · UNKNOWN · sponsor: **Sheba Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Neovascular Age Related Macular Degeneration

## Interventions

- **DEVICE:** Pascal Dynamic Contour Tonometer
- **DRUG:** Ranibizumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00640640
- **Lead sponsor:** Sheba Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** 2008-12
- **Final completion:** 2009-02
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2008-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00640640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00640640, "The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00640640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*